.jpg)
The Asco Post recently interviewed Dr. Jean Pierre Bizzari, the Executive Vice President of Celgene, a multinational bioparmaceutical company. The interview covered various aspects of research and development (R&D)…
According to a story from Rare Disease Report, the US Food and Drug Administration (FDA) has announced its approval of a combination therapy from Janssen which consists of ibrutinib plus…
According to a story from Onclive, combination therapies are likely to play an increasing role in the treatment of chronic lymphocytic leukemia. In this video, leukemia treatment experts discuss the…
According to a story from PR Newswire, the 60th Annual Meeting of the American Society of Hematology has been generating a lot of press lately as many groundbreaking studies, research,…
According to a story from BioPortfolio, the global biopharmaceutical company Celgene Corporation recently announced the release of early data from the dose-escalation portion of a Phase 1/2 clinical trial of lisocabtagene…
According to a story from PR Newswire, presentations at the 60th annual American Society of Hematology Meeting and Exposition are highlighting the results of four large scale clinical trials that…
You might have heard of the recent political situation where President Donald Trump criticized retired Adm. William H. McRaven on a number of issues. We're not going to dig into…
According to a story from The Oncology Times, the US Food and Drug Administration (FDA) has been moving forward with several treatments and potential treatments for a variety of different…
According to a story from Hematology Times, a recent phase 2 study found that a three-part combination treatment could be a valuable treatment option for patients with chronic lymphocytic leukemia.…
According to CureToday.com, those who have been diagnosed with chronic lymphocytic leukemia, CLL, are now living longer than ever before. This feat can be attributed to the influx of…
According to a story from BioPortfolio, the U.S. Food and Drug Administration (FDA) has recently approved a new combination therapy for the treating small lymphocytic lymphoma and chronic lymphocytic leukemia…
A phase 3 Murano clinical trial has shown that combining the drugs Venclexta (venetoclax) and Rituxan (rituximab) could be an effective treatment for chronic lymphocytic leukaemia, reports Cancer Updates, Research,…
According to a story from adc.net.au, an innovative new cancer treatment regimen is responsible for doubling survival rates for patients with certain types of rare, difficult-to-treat blood cancers. This combination…
A video of former US Vice President Joe Biden on the talk show The View comforting co-host Meghan McCain has been making the rounds on the Internet the last few…
While multiple myeloma treatment has made significant advances in recent years, the prospect of a cure remains as elusive as ever—just as it does for all cancers. But that may…
During this year’s International Workshop on chronic lymphocytic leukemia (CLL), Shih-Shih Chen, PhD, was recognized for her innovative research. Her research could mean a cure is around the corner for CLL.…
On June 21st, Targeted Oncology posted the results from a phase 2 clinical trial for chronic lymphocytic leukemia (CLL). The trial examined the effects of combing two therapies--obinutuzumab and bendamustine.…
Communication in the medical field doesn’t happen as much as it should. But, when it does, great discoveries often occur. The thing is, science is complicated. Researchers have so much…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
